Geode Capital Management LLC Sells 3,854 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Geode Capital Management LLC trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,823,994 shares of the life sciences company’s stock after selling 3,854 shares during the period. Geode Capital Management LLC owned about 2.36% of Integra LifeSciences worth $33,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Sachem Head Capital Management LP bought a new position in shares of Integra LifeSciences during the third quarter valued at approximately $44,153,000. Glenmede Trust Co. NA increased its holdings in shares of Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after acquiring an additional 405,624 shares during the period. Cooke & Bieler LP raised its position in shares of Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after acquiring an additional 388,710 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Integra LifeSciences by 64.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after purchasing an additional 335,557 shares during the last quarter. Finally, Systematic Financial Management LP boosted its position in Integra LifeSciences by 540.6% during the second quarter. Systematic Financial Management LP now owns 397,474 shares of the life sciences company’s stock valued at $11,582,000 after purchasing an additional 335,424 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART opened at $22.13 on Thursday. The stock has a 50-day moving average of $22.69 and a two-hundred day moving average of $23.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.71 billion, a P/E ratio of -245.86, a P/E/G ratio of 0.82 and a beta of 1.15. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the prior year, the company earned $0.76 EPS. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. As a group, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by insiders.

Analyst Ratings Changes

IART has been the subject of a number of recent research reports. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley began coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Finally, Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.